new_0222_0271|VERV|0|ps_ratio|price_to_book_value|peg_ratio|price|short_interest|dividend_yield|earning_yield|market_cap|pe_ratio|consensus_recommendation|price_target_num_est|price_target|sales_est_1y|sales_est_0y|eps_est_1y|eps_est_0y|ebitda_est_0y|ebitda_est_1y|revenues|ebitda|net_income|price_next_month|price_second_month
new_0222_0271|VERV|1|Verve Therapeutics Inc PS Ratio|Verve Therapeutics Inc Price to Book Value|Verve Therapeutics Inc PEG Ratio|Verve Therapeutics Inc Price (USD)|Verve Therapeutics Inc Short Interest|Verve Therapeutics Inc Dividend Yield|Verve Therapeutics Inc Earnings Yield|Verve Therapeutics Inc Market Cap (USD)|Verve Therapeutics Inc PE Ratio|Verve Therapeutics Inc Consensus Recommendation|Verve Therapeutics Inc Price Target Num Estimates|Verve Therapeutics Inc Price Target (USD)|Verve Therapeutics Inc Revenue Estimates for Next Fiscal Year (USD)|Verve Therapeutics Inc Revenue Estimates for Current Fiscal Year (USD)|Verve Therapeutics Inc EPS Estimates for Next Fiscal Year (USD)|Verve Therapeutics Inc EPS Estimates for Current Fiscal Year (USD)|Verve Therapeutics Inc EBITDA Estimates for Current Fiscal Year (USD)|Verve Therapeutics Inc EBITDA Estimates for Next Fiscal Year (USD)|Verve Therapeutics Inc Revenue (Quarterly) (USD)|Verve Therapeutics Inc EBITDA (Quarterly) (USD)|Verve Therapeutics Inc Net Income (Quarterly) (USD)||
new_0222_0271|VERV|2|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_money_USD_price|figure_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_whole_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric||
new_0222_0271|VERV|4|quarterly|daily|quarterly|daily|monthly|daily|daily|daily|quarterly|monthly|monthly|monthly|monthly|monthly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0271|VERV|5||1.43827160494||1.43859649123|15.3571428571|1.43859649123|1.43859649123|1.43859649123||11.5|23|23|20.375|18.4|20.375|15.3333333333|63|63||91.3333333333|91.3333333333||
new_0222_0271|VERV|6||162||171|14|171|171|171||16|8|8|8|10|8|12|2|2||6|6||
new_0222_0271|VERV|7|daily|daily|daily|market_daily|daily|daily|daily|daily|daily|daily|daily|daily|daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly||
new_0222_0271|VERV|20200315||||||||||||||||||||-7.204|-5.603||
new_0222_0271|VERV|20200615||||||||||||||||||||-6.4|-7.58||
new_0222_0271|VERV|20200915||||||||||||||||||||-8.348|-8.99||
new_0222_0271|VERV|20201215||||||||||||||||||||-17.347|-23.531||
new_0222_0271|VERV|20210315||||||||||||||||||||-13.767|-13.263||
new_0222_0271|VERV|20210615||7.1259||31.92|1138586||-5.7161|1471.844||||||||||||-16.607|-52.965|38.05|60.25
new_0222_0271|VERV|20210715||6.285||53.14|1538887||-15.4775|2547.9036||1.5|3|68.6667|||-2.3897|-3.2692|-91.5748|-116.1098||||50.14|59.43
new_0222_0271|VERV|20210815||7.7054||65.15|1587298||-12.6243|3123.7471||1.5|3|69.6667|||-2.4722|-6.9033||||||61.74|69.96
new_0222_0271|VERV|20210915||8.3696||70.7|1887219||-11.6333|3393.0203||1.5|4|66.75|||-2.4877|-5.9575||||-23.09|-22.749|71.46|47
new_0222_0271|VERV|20211015||6.1967||49.61|2979226||-16.905|2385.3183||2|3|61|||-2.4971|-3.63||||||50.34|46.39
new_0222_0271|VERV|20211115||6.2042||49.67|3844327||-16.8846|2388.2031||2|3|61|||-2.5221|-3.3093|-91.5748|-116.1098||||52.94|34.08
new_0222_0271|VERV|20211215||4.1684||33.31|5660317||-25.1774|1604.576||1.8|5|70.4|||-2.524|-5.57||||||32.94|36.87
new_0222_0271|VERV|20220115||4.9255||39.36|6194372||-21.3074|1896.0106||1.6667|5|70.4||||-2.3667||||||35.99|28.82
new_0222_0271|VERV|20220215||3.6278||28.99|||-28.9292|1396.4773||||||||||||||28.04|26.76